|Bladder Cancer||Benign Prostatic Hyperplasia (BPH)|
|Erectile Dysfunction (ED)||Hypogonadism|
|Kidney Cancer||Kidney Stones|
|Overactive Bladder||Premature Ejaculation|
|Prostate Cancer||Prostate Specific Antigen (PSA)|
|Reproductive Medicine||Urinary Incontinence|
|Urinary Tract Infections (UTI)|
Most stones patients do not need additional imaging with computed tomography, study finds.
Radiotherapy given within 6 months of radical prostatectomy reduces cancer-specific mortality in men with highly aggressive disease.
Joint committee also calls for drug makers to run heart-risk tests on popular 'Low T' products.
FDA has approved a supplemental new drug application for Stendra (avanafil) taken early as ~15 minutes before sexual activity.
High rates of preserved sexual function with combination beam plus brachytherapy.
Utilization rates jumped by double digits across prostate cancer risk groups from 2004 to 2011.
American College of Physicians guidelines addresses nonsurgical management of urinary incontinence in women.
Men with male pattern baldness may face a higher risk of aggressive prostate cancer.
This benefit is not seen in patients who undergo radical prostatectomy, according to an updated meta-analysis.
Black prostate cancer patients more likely to develop aggressive disease earlier than white patients.
Low-dose aspirin decreased the likelihood of acute genitourinary toxicity in prostate cancer by 27%.
Enzalutamide and abiraterone may not benefit men with metastatic castration-resistant prostate cancer who have AR-V7 in circulating tumor cells.
However, they are more likely to die from causes other than prostate cancer than men with normal metabolic levels.
The drug is now also approved for use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Study finds a 15-year cancer-specific survival rate of 94%; hormone therapy for more than 6 months decreases all-cause survival.
Study also finds increase in overall cancer rate among African-American children and adolescents.
Expert panel to decide whether prescribing information on testosterone drugs should be changed.
The 3-year survival rates for patients diagnosed during 2006-2007 were similar to those diagnosed during 2001-2005.
Author writes that doctors can and should take advantage of social media marketing opportunities.
It is associated with a 20-fold increased likelihood of the malignancy, British study shows.